Belite Bio, Inc
Financials
Valuation Metrics
Belite Bio, Inc's Market Cap is $6.22B. At end of 2025 it was $5.36B. Ranked #1177 of 3,118 in US market (top 38%), #385 of 1,474 on NASDAQ (top 26%), #66 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 25%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $6.22B | US#1,177/3,118 Sec#66/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-102M | US—/3,118 Sec—/265 |
| Total Assets | $792M | US#2,567/3,118 Sec#120/265 |
| Net Assets | $777M | US#1,932/3,118 Sec#79/265 |
| Employees | 41 | US#2,717/3,118 Sec#212/265 |
| Value | ||
| P/B | 8.01x | US#2,529/3,118 Sec#184/265 |
| FCF Yield | -0.00% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -13.18% | US#2,403/3,118 Sec#87/265 |
| ROA | -12.93% | US#2,702/3,118 Sec#110/265 |
| Financial Health | ||
| Debt Ratio | 1.92% | US#16/3,118 Sec#4/265 |
| Total Debt | $0.00 | US—/3,118 Sec—/265 |
| FCF | $-10563.00 | US#2,300/3,118 Sec#86/265 |
| Cash | $0.00 | US—/3,118 Sec—/265 |
| Current Ratio | 33.56x | US#74/3,118 Sec#9/265 |
| Performance | ||
| 1Y Return | 58.13% | US#395/3,118 Sec#68/265 |
| 1M Return | -8.65% | US#2,388/3,118 Sec#174/265 |
| From 52W High | -22.43% | US#1,596/3,118 Sec#93/265 |
| 1Y MDD | -29.10% | US#1,232/3,118 Sec#62/265 |
| Trading | ||
| Volume | 217,774 shares | US#2,593/3,118 Sec#244/265 |
| Trading Value | $33M | US#1,561/3,118 Sec#109/265 |
| Per Share | ||
| EPS | $-2.55 | US—/3,118 Sec—/265 |
| BPS | $19.37 | US#1,269/3,118 Sec#30/265 |
Company Info
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.